Systematic Reviews
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2019; 11(9): 741-749
Published online Sep 15, 2019. doi: 10.4251/wjgo.v11.i9.741
Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review
Sara Jamel, Karina Tukanova, Sheraz Markar
Sara Jamel, Karina Tukanova, Sheraz Markar, Department Surgery and Cancer, Imperial College London, London W2 1NY, United Kingdom
Author contributions: Jamel S, Tukanova K and Markar M contributed equally to this work; Jamel S, Tukanova K and Markar M designed the study; Jamel S and Tukanova K performed the search and checked articles for inclusion; All authors contributed to the analytical tools used and analysed the data, wrote the manuscript and have read and approved the final manuscript.
Conflict-of-interest statement: The authors declared no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Sheraz R Markar, PhD, Surgeon, Division of Surgery, Department of Surgery and Cancer, Imperial College London, 10th Floor QEQM Building, St Mary’s Hospital, South Wharf Road, London W2 1NY, United Kingdom. s.markar@imperial.ac.uk
Telephone: +44-207-8862125 Fax: +44-207-8862125
Received: February 20, 2019
Peer-review started: February 22, 2019
First decision: June 5, 2019
Revised: June 25, 2019
Accepted: July 29, 2019
Article in press: July 29, 2019
Published online: September 15, 2019
Processing time: 204 Days and 17.4 Hours
Core Tip

Core tip: Oesophageal cancer often presents with early metastatic spread, which carries a poor prognosis. Some patients may have limited metastatic disease that can be treated with loco-regional therapy. The guidelines for the management of oligometastasis in oesophageal cancer are however not clearly established and survival outcomes remain unclear. The aims of this review were to assess the current practice for the treatment of oligometastatic oesophageal cancer and factors affecting survival following treatment of oligometastasis. A total of 14 publications were included assessing the management and survival outcomes and the majority of these studies opted for aggressive treatment in appropriate patient selection.